Engineering Replacement Tissue to Reverse Damage to the Central Nervous System

BE Therapeutics is an early-stage biotech startup developing technology to engineer functional brain and spinal cord tissue. Our mission is to engineer stem cell derived replacement tissue to reverse age-related and other forms of damage to the brain, ensuring indefinite function.

Stroke, trauma, neurodegeneration, and aging all cause permanent damage to the CNS.

No treatments enable afflicted individuals to regain lost functions.

BE Therapeutics aims to change this.

SUPPORTERS

TECHNOLOGY

Rather than try and “re-invent the wheel”, the technology at BE Therapeutics is guided by how our human brains first develop during early neurodevelopment. Namely, BE Therapeutics is engineering a precursor tissue that mimics normal developmental brain tissue, with the proper cell types, signaling cues, and structure, which allow the tissue to mature normally after transplantation, integrate with the host, and encode useful information for the patient.

BE Therapeutics’ tissue and methodologies will be used in pre-clinical and clinical applications. The initial focus is on replacing damaged neocortical tissue, followed by other parts of the CNS.

Multi-cell type structured brain tissue

Our latest “PiaGel” biomaterial enables the rapid generation of vascularized tissue constructs.

“PiaGel” supports the growth and maturation of cortical precursors.

MEET THE TEAM

  • Chief Scientific Officer

    Philip is a serial entrepreneur, building companies that develop new therapies for neurological diseases. Leveraging over 20 years of experience in cell and gene therapy, Philip has developed iPSC -derived cell products to treat Type 1 diabetes, neurodegenerative diseases and liver diseases at Smith Therapeutics, AZTherapies, Sigilon Therapeutics and Flagship Pioneering.

  • Senior Clinical Advisor

    Dr. David J. Altschul, MD, FAANS, FCNS, serves as the Chief of the Division of Cerebrovascular Neurosurgery, Surgical Director of the Comprehensive Stroke Center, Associate Residency Program Director, and Professor of Neurosurgery and Radiology at Montefiore-Einstein. He is a dual trained open-endovascular neurosurgeon, having completed his neurosurgical residency at Montefiore-Einstein and a neuroendovascular fellowship under the guidance of Dr. Alejandro Berenstein at Mt. Sinai.

    Throughout his esteemed career, Dr. Altschul has garnered recognition for his exceptional patient care and unwavering commitment to excellence in neurovascular surgery. Renowned for his innovative treatment approach, he leverages cutting-edge technology and research to ensure optimal care for his patients. Actively engaged in numerous research initiatives focusing on new device developments and clinical trials, he has established a thriving Cerebrovascular research lab at Montefiore-Einstein. Dr. Altschul takes great pride in his dedication to mentorship, consistently offering his time to guide students at various stages of their learning journeys.

  • Lead Scientist

    Wyndham began his scientific career studying Physics at the College of William & Mary in Williamsburg, VA; it was during this time that he had his first experience conducting research in biology and biophysics. Following his interest in applying techniques from the physical sciences to the biological world, Wyndham then completed his PhD in Biomedical Engineering at the University of Miami under Dr. Noel Ziebarth, where he was awarded the Graduate School Dean’s Fellowship.

    After graduation, Wyndham furthered his training in stem cell biology and regenerative medicine as a Postdoctoral Fellow at the National Institutes of Health under Dr. Tiansen Li, where he learned to utilize functional biomaterials to direct the growth and behavior of human stem cell derived retinal organoids.

    Wyndham now serves as the Lead Scientist at BE Therapeutics where he is developing novel biomaterial constructs for the creation of new functional brain tissue to be engrafted into damaged areas of the human brain.

Let’s work together

Interested in our work? Reach out:

contact@betherapeutics.com